Avid plans expansion with focus on biologics development
There is no slowdown in sight, says Avid Bioservices CEO, as the company today announces further expansion to support new client projects and optimize its novel CHO-based expression system.
There is no slowdown in sight, says Avid Bioservices CEO, as the company today announces further expansion to support new client projects and optimize its novel CHO-based expression system.
GB Sciences has transferred a cannabinoid-based, time-released neuropathic pain formula from Spain to the US.
STA Pharmaceutical is manufacturing PhoenixMD’s kinase inhibitor drug candidate for IND-enabling toxicology studies and a Phase I study in women with triple-negative breast cancer.
Letter to the editor
A continued need for specialized services and expertise will keep smaller firms in business – though many have forecasted the “death of small- to mid-sized CROs” as the industry continues to consolidate, say experts.
Acurian and Synexus have introduced a new clinical trial enrollment solution for patients with nonalcoholic fatty liver disease, which is often underdiagnosed.